Gilead’s Core Business Is Accelerating, but Will an $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (NASDAQ: GILD) delivered a second-quarter 2026 earnings report that looked contradictory on the surface. Commercial product sales rose at a double-digit pace, while the company posted one of the largest quarterly losses in its recent history. The disconnect was not caused by a collapse in demand. It stemmed from more than $11 billion in acquired research and development expenses tied to a series of pipeline deals.

That distinction matters for investors. The core business is healthy enough to support expansion, but management has spent heavily on therapies that have yet to prove their commercial value. The key question is whether those bets will pay off in time.

Sales excluding Veklury, Gilead’s COVID-19 medicine, increased 10% to $7.6 billion, showing that growth is no longer tied to a shrinking pandemic product. HIV remained the main engine, with sales up 12% to $5.7 billion. Biktarvy revenue rose 7% to $3.8 billion, Descovy climbed 48% to $967 million, and Yeztugo, the twice-yearly injectable HIV prevention medicine, contributed $232 million in its launch quarter. The early performance gives Gilead another potential growth driver in a therapeutic area where it already has strong commercial scale.

Progress outside HIV was also visible. Liver-disease revenue climbed 10% to $877 million, helped by Livdelzi, which more than doubled to $167 million from $78 million a year earlier. Trodelvy, the breast-cancer therapy, rose 26% to $457 million on stronger demand. As a result, management raised the lower end of its 2026 product-sales guidance to $30.1–$30.4 billion from $30.0–$30.4 billion. Excluding Veklury, the guidance range moved to $29.8–$30.1 billion, up from $29.4–$29.8 billion.

The acquisitions behind the quarterly loss also have a clear strategic rationale. Buying Arcellx gave Gilead full control of anito-cel, an investigational CAR-T therapy for multiple myeloma, while removing future profit-sharing, milestone, and royalty obligations. The FDA has accepted the application and set a target decision date of December 23, 2026. Gilead expects the transaction to become accretive in 2028, assuming approval. Tubulis adds next-generation antibody-drug conjugate technology, including GS-8824, and Ouro Medicines brings gamgertamig, an investigational treatment for autoimmune diseases. Taken together, the deals could reduce Gilead’s reliance on HIV and expand its presence in oncology and inflammation.

The cost of that expansion is substantial. Gilead recorded $11.2 billion in acquired in-process R&D expenses, including $7 billion for Arcellx, $3.1 billion for Tubulis, and $1 billion for Ouro Medicines net of the Lakefront collaboration. Those charges produced a GAAP loss of $8.45 per share and a non-GAAP loss of $6.75 per share. Cash, cash equivalents, and marketable debt securities fell to $3.2 billion at the end of June from $10.6 billion at the end of 2025. Gilead used $11.3 billion in acquisition-related cash outflows during the first half and raised $4.1 billion through debt financing.

The company is therefore taking on financial risk before the acquired programs have generated meaningful revenue. Anito-cel is closest to a possible launch, but its payoff depends on regulatory approval and successful commercialization. The Tubulis and Ouro assets carry additional clinical-development risk. Gilead’s record in oncology is also mixed. Trodelvy is growing, but cell-therapy sales fell 14% to $417 million amid competitive pressure. Yescarta declined 12% to $346 million, and Tecartus fell 24% to $70 million. Those results are a reminder that promising science does not automatically translate into durable commercial performance.

For now, Gilead’s core business looks solid enough to support its more ambitious pipeline strategy. HIV remains a reliable source of cash, and Yeztugo, Livdelzi, and Trodelvy offer credible avenues for additional growth. The acquisitions could eventually produce a more diversified company, but investors are being asked to accept significant clinical, integration, and balance-sheet risk before that outcome becomes visible. Gilead has already paid much of the price. The next test is whether anito-cel and the broader acquired pipeline can generate returns that justify it.